2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2969

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
Abstract Number: 2970

Inhibition of Radiographic Progression in Psoriatic Arthritis By Adalimumab Independent of the Control of Clinical Disease Activity
Abstract Number: 2971

What Do Reduced 28 Joint Counts Miss in Patients with Psoriatic Arthritis?
Abstract Number: 2972

Risk of Myocardial Infarction and Cerebrovascular Accident in Ankylosing Spondylitis: A General Population-Based Study
Abstract Number: 2973

Detection of Clinical Signs of Arthritis and Subclinical Evidence of Inflammation in Psoriasis Patients with Risk for Arthritis: Value of Clinical Examination, Ultrasound and Fluorescence-Optical Imaging – Results from the Prospective Multicentre Xciting Study
Abstract Number: 2974

B Cell Binding Autoreactive VH4.34 Antibodies Are Specific to Lupus, Consist of Diverse Isotypes, and Are Associated with High Disease Activity and Lupus Nephritis
Abstract Number: 2975

Using Immune and Metabolic Phenotyping to Understand the Immunopathogenesis of Juvenile-Onset SLE and Stratify Patient Groups
Abstract Number: 2976

Identification of Systemic Lupus Erythematosus Causal Risk Variant Candidates Spanning the UBE2L3 Haplotype
Abstract Number: 2977

Molecular Phenotypes Associated with Clinical Disease Activity in Adult Systemic Lupus Erythematosus
Abstract Number: 2978

OX40/OX40L Axis Impairs Follicular and Natural Regulatory T Cell Function in Human Systemic Lupus
Abstract Number: 2979

The Expression of Mitochondrial Molecules in Microparticle Immune Complexes in the Blood of Patients with Systemic Lupus Erythematosus
Abstract Number: 2980

Chemokine CCL21 As a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis
Abstract Number: 2981

Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the Fasscinate Trial
Abstract Number: 2982

Morbidity and Mortality of Scleroderma in African Americans
Abstract Number: 2983

Predictors for Disease Worsening Defined By Organ Failure in Diffuse Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].